Ozempic’s Limits: Novo Nordisk’s Alzheimer’s Gamble Falls Short, Exposing the Boundaries of GLP-1 Hype
Novo Nordisk, the pharmaceutical powerhouse behind the blockbuster weight-loss and diabetes drug Ozempic, has faced a rare setback. The company’s pill-based version
by 
Josh Weiner
Josh Weiner